

Insys Therapeutics, Inc.  
Form 8-K  
March 03, 2015

---

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

---

**FORM 8-K**

---

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 3, 2015**

---

---

**Insys Therapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

---

**Delaware**  
**(State of incorporation)**

**001-35902**  
**(Commission File No.)**

**51-0327886**

**(IRS Employer  
Identification No.)**

**1333 South Spectrum Blvd, Suite 100**

**Chandler, Arizona 85286**

**(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (480) 500-3127**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

---

**Item 2.02 Results of Operations and Financial Condition.**

On March 3, 2015, Insys Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2014. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Forward-Looking Statements**

Statements included in the exhibits hereto that are not a description of historical facts are forward-looking statements. Words such as “believes,” “would,” “anticipates,” “plans,” “expects,” “may,” “intend,” “will,” and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that any of our plans will be achieved. These forward-looking statements are based on management’s expectations on the date of this current report. Actual results may differ materially from those set forth in this release due to various risks and uncertainties including, without limitation, risks detailed in our filings with the Securities and Exchange Commission and in the press release attached hereto at Exhibit 99.1. Forward-looking statements speak only as of the date of this current report, and we undertake no obligation to update or revise these statements, except as may be required by law.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

**Exhibit**

**Description**

<b>No.</b>	
99.1	Press release issued by Insys Therapeutics, Inc. on March 3, 2015 announcing financial results for the fourth quarter and year ended December 31, 2014



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 3, 2015 Insys Therapeutics, Inc.

By: /s/ Darryl S. Baker  
Darryl S. Baker  
Chief Financial Officer